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(MU) were delivered at each angle: The reference dose 
without couch attenuation is the average dose at 0⁰,90⁰ and 
270⁰. Gantry angles ranging from 235⁰ to 223⁰ in 1⁰ 
increments are used to measure the edge attenuated dose. 
And gantry angles ranging from 220⁰ to 180⁰ in 10⁰ 
increments to measure the dose attenuation of the central 
region of the couch. 
Skin dose was measured with radiochromic films and FilmQA 
Pro. Several films were placed between RW3 slabs in 
different depths.The center of RW3 phantom coincides with 
linac isocenter.  
First,films were located at the surface, 0.5cm and 1.5cm 
from the surface, and in the center of the RW3 phantom. 
Then 200MU were delivered with an open 10x10 field and 
with zero gantry angle. The irradiated films were removed 
and other films were placed under the phantom, 0.5cm and 
1.5cm from the couch and in the center. The opposite beam 
was delivered, so we measure the effect of the couch to the 
dose distribution in the buildup region. 
 
Results: Table 1A Comparison results between measured and 
calculated relative transmitted dose (T%), with and without 
the couch. Table 1B Evaluation of skin dose increment and 
comparison results between scanned and calculated 
increment of skin dose. 
 
 
Conclusion: The couch model improves the discrepancy 
between measured and computed attenuated dose. If we 
take into account the couch in treatment planning 
calculations, this average difference decreases from 3.3% to 
0.4%. The couch increases 4 times the skin dose and the 
couch model provides an accurate calculated dose in the 
buildup region. 
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Purpose or Objective: Dosimetry Check (DC) is a commercial 
software that allows reconstruction of 3d dose distributions 
using transit and through-air EPID images. DC is composite of 
two parts: a deconvolution kernel that converts EPID images 
to fluence, and a pencil beam algorithm to calculate the 
dose. It can be used for pre treatment QA verification and for 
in vivo dosimetry. In this work we evaluated the suitability of 
DC software for in vivo dosimetry of VMAT treatments. 
 
Material and Methods: DC (v4.10) was used along with Elekta 
Synergy® Linac (6 and 10 MV beams) equipped with a-Si 
Electronic Portal Imaging Device (EPID) Iview-GT. Twenty 
VMAT (5 prostate, 5 whole pelvis, 5 lung, 5 head and neck), 
elaborated by treatment planning system (TPS) Elekta 
Monaco® 5.0 were measured. Through-air (EPID T-A) and 
transit EPID images were used for three dimensional dose 
maps reconstruction in homogeneous phantoms. Octavius 4D 
with 729 2D array was used as reference. Gamma analysis at 
3% local dose /3mm DTA was performed. Doses from though-
air measurements were also reconstructed in the planning CT 
(T-A in plan TC) and compared with the treatment planning 
dose maps.Gamma pass rate of DC dose maps were compared 
with those of 729 in the Octavius 4D.  
 
Results: 
 
 
Table1 Gamma pass rate. EPID T-A are computed in the 
synthetic Ocatvius 4D phantom,  
EPID transit is measured and computed in the homogeneous 
Octavius II phantom. 
 
 
 
Figure1: Results of a whole pelvis SIB treatment. In the upper 
part comparison of profiles for Octavius 4D (A), T-A EPID (B) 
and Transit EPID (C). In yellow the TPS profile. The lower 
part of the image contains central coronal map of gamma>1 
points. In D the comparison of DVH measured by DC in plan 
CT (solid) versus TPS (dotted lines) is shown.  
Gamma pass rates are shown in the table1.The assessment of 
VMAT plans shows a mean of 93.9% points with gamma<1 for 
Octavious 4d (3.5% SD), 89.2% and 7.9%SD for EPID T-A, 89% 
and 8.5% SD for EPID Transit and 89.8% and 6.1%SD for T-A in 
plan CT. Transit and through-air EPID acquisitions produced 
similar gamma pass rates.Through-air EPID images computed 
by DC in the plannning CT showed gamma pass rate in 
agreement with those of Octavious 4d in the prostate, whole 
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pelvis and head and neck, in lung instead, gamma pass rates 
were lower in 4/5 cases.  
 
Conclusion: DC is a suitable tool for VMAT in vivo dosimetry. 
The pencil beam algorithm can be inaccurate in the presence 
of low-density inhomogeneities. 
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Purpose or Objective: Accurate beam modelling is an 
essential function of a treatment planning system (TPS) to 
ensure that plans can be calculated that are deliverable 
within clinically acceptable tolerances. The purpose of this 
work is to evaluate the computed integral depth dose (IDD) 
curves of four commercially available proton TPSs, 
benchmarked against measured data. The four TPSs 
(EclipseTM, XiO®, Pinnacle3, RayStation®) were 
commissioned using pencil beam scanning data from the 
University of Pennsylvania (UPenn) facility. 
 
Material and Methods: A water cube phantom (40cm3) was 
created in each TPS for calculation of IDD curves. Calculation 
grid size set to 1mm in all TPSs. Individual IDDs for 27 
nominal energies, ranging from 100 to 226.7MeV, were 
calculated by integrating the calculated depth dose 
distributions. These were all benchmarked against measured 
data from UPenn, comparing the clinical range at 80% distal 
dose (D80), Bragg peak width between distal and proximal 
80% (D80-P80), range at 0.5% (R0.5), and distal penumbra 
between D80 and R0.5. Gamma-index analysis with pass 
criteria of 1mm/1% was also used to compare computed and 
measured IDDs. 
 
Results: Mean percentage of IDDs with >95% pass rate for 
1mm/1% criteria were 96.7% (SD 4.9) for XiO®, 94.1% (SD 8.9) 
for EclipseTM, 95.4% (SD 8.6) for RayStation®, and 49.2 (SD 
26.0) for Pinnacle3. Maximum differences between computed 
and measured IDD data are shown below. No correlation with 
nominal energy was observed. 
 
 
Conclusion: Characteristics of computed IDDs were compared 
to measured data for four commercially available TPSs. All 
were within clinically acceptable tolerances, with XiO 
showing the closest agreement. Differences observed were 
attributed to TPS specific beam modelling. Further 
investigation will assess the cumulative impact of these 
discrepancies on verified clinical treatment plans. 
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Purpose or Objective: One of the clinical issues our institute 
faces regarding in vivo EPID dosimetry is the number of raised 
alerts. For example, alerts are raised for 49% of the 
treatments in case of head-and-neck (H&N) VMAT 
treatments; an alert is raised when dosimetry results are 
found deviating according to statistics derived from the 
histogram of 3D γ-analysis results. These alerts are mostly 
found to be patient-related or attributable to limitations of 
our back-projection and dose calculation algorithm. After 
inspection, an intervention is considered for only 0.3% of the 
treatments. The purpose of this study is to develop a 
principal component analysis (PCA) based classification 
method to improve the specificity of our EPID dosimetry 
system. In particular, in contrast to our current classification 
method, PCA allows for the spatial distribution of γ-values to 
be taken into account for deviation detection. 
 
Material and Methods: The input for PCA consisted of 3D γ-
distributions (3%/3mm), one per treatment arc per fraction. 
In total, 2024 3D γ-distributions from 499 H&N VMAT 
treatment-plans were included. As an initial choice, 
components describing at least 1% of the variance were 
selected. The distribution of variances over the components 
was inspected to validate this choice. Using these 
components, new 3D γ-distributions were created by 
projecting each input 3D γ-distribution on only these 
components and then projecting the result to the original 
coordinate system of the 3D γ-distributions. If the selected 
components describe the original γ-distribution well, the new 
and original γ-distributions will be similar. This similarity was 
quantified by the root mean square (RMS) d of the difference 
between the two γ-distributions; a γ-distribution was marked 
as deviating when d exceeded a threshold. All true positive γ-
distributions (n = 2) in the dataset, as identified by 
experienced medical physicists, were used to determine this 
threshold for identification of alerts. 
 
Results: The first 16 components were each found to 
describe at least 1% of the variance; cumulatively, they 
account for 83% of the variance in the dataset. Figure 1 
shows the cumulative variance accounted for as a function of 
selected components and indicates that the choice for 
selecting components is reasonable. After finding and 
applying the appropriate threshold for detecting the 
identified true positives, a drop in alert rate from 49% to of 
11% was observed, corresponding to an increase in specificity 
from 0.51 to 0.89. 
 
 
 
Conclusion: The PCA-based classification method presented 
in this study enhances the specificity of deviation detection 
in 3D in vivo EPID dosimetry of H&N VMAT from 0.51 to 0.89, 
compared to our current clinical γ-histogram based method. 
Before clinical implemention, a rigorous validation is 
required. 
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